Peptide Profile
Vilon
Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance
Dose Range
5-10mg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
12+ weeks
Onset
Gradual (3-4 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C11H21N3O5
Molecular Formula
275.3 g/mol
Molecular Weight
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids
Half-Life
Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure
Bioavailability
45234-02-4
CAS #
7010502
PubChem ID ↗
Developed By · 1970s-1980s (characterized as part of Khavinson's systematic peptide bioregulator research program beginning in 1973)
Biocrown Pharmaceuticals Inc.
Biocrown Pharmaceuticals Inc.
Primary Benefits
Amino Acid Sequence
GGGVA-GPQGIAG-GSKGPD-GVGGADosing
How much
do I take?
Starting Dose
200-500 mcg subcutaneously once daily
Begin with the conservative research protocol. Reconstitute lyophilized Vilon in bacteriostatic water or physiological saline. Administer subcutaneously, rotating injection sites. This ultra-short dipeptide is rapidly absorbed. Effects are gradual — immune and epigenetic changes build over the treatment course. Monitor for any injection site reactions.
Standard Dose
5 mg subcutaneously once daily
Standard clinical protocol used in Russian bioregulator therapy. Administer subcutaneously once daily for 5-10 consecutive days. Repeat courses every 3-6 months for sustained immune and geroprotective benefits. Can be combined with Epithalon for comprehensive anti-aging or with Vladonix for enhanced immune support. The SIRT1 upregulation and PARP downregulation initiated during treatment persist beyond the active course.
Advanced Dose
10 mg subcutaneously once daily
Extended protocol for individuals with significant immune compromise or advanced age. Used in clinical studies as adjuvant therapy for cancer patients alongside radio/chemotherapy. Often combined with complementary bioregulators: Thymalin for full-spectrum thymic support, Epithalon for pineal/melatonin function, and Cerluten for neuroprotection. Repeat courses every 3-6 months. Medical supervision recommended for advanced protocols.
Timing
Best time to take
Administer Vilon at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Vilon injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Vilon should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Immune system restoration in aging individuals with declining thymic function
Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive immunomodulatory support during cancer treatment protocols
Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for anti-aging and immune support
Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)
- ×Pregnancy and breastfeeding — insufficient reproductive safety data
- ×Active autoimmune disease in flare without medical supervision
- ×Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Vilon use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Vilon vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.
Safety data comes primarily from Russian clinical experience and unpublished manufacturer studies; limited peer-reviewed Western data exists. No Phase 3 controlled efficacy trials have been published in major journals. Immunostimulatory mechanism could theoretically exacerbate autoimmune conditions, requiring baseline immune status assessment. Long-term safety beyond 2-3 months of use is incompletely characterized in English-language literature.
Common Side Effects
Experienced by some users
Injection site reaction
Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. Common with injectable peptide bioregulators.
Management: Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Mild fatigue
Slight fatigue during the initial days as the immune system recalibrates in response to enhanced T-cell activation and cytokine modulation.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Mild headache
Transient headache during the first few days of treatment, potentially related to immune activation and cytokine level changes.
Management: Ensure adequate hydration. Standard analgesics if needed. Usually self-limiting.
Digestive changes
Mild gastrointestinal changes (increased digestive activity, slight changes in bowel habits) reflecting Vilon's enhancement of digestive enzyme activity throughout the GI tract.
Management: Generally benign — indicates active enzyme normalization. Eat regular meals. Should stabilize within days.
Less Common
- •Flu-like symptoms
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Vilon
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Vilon should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) — Vilon's immunostimulatory effects may counteract immunosuppression - Use with caution—discuss with your healthcare provider.
- !High-dose corticosteroids — may interfere with Vilon's T-cell activation and cytokine regulation mechanisms - Use with caution—discuss with your healthcare provider.
- !Other potent immunostimulants at high doses without medical supervision — risk of immune overactivation - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Vilon. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Days 1-5 (during treatment course)
What you might notice
- •Minimal noticeable changes during the initial days — epigenetic mechanisms are building
- •Mild injection site reactions that resolve within hours
- •Possible mild fatigue or flu-like symptoms as immune modulation begins
- •The dipeptide-DNA interactions at SIRT1/PARP promoters are already underway
What's normal
- •Effects are subtle initially — Vilon works at the gene expression level through DNA promoter binding
- •SIRT1 upregulation and PARP downregulation are beginning but protein synthesis changes take days
- •Thymocyte activation through the sphingomyelin pathway is starting to enhance T-cell development
What's next
- →Continue daily injections for the full course duration (5-12 days)
- →Immune improvements and geroprotective effects will continue building
- →The most significant cellular changes occur during and shortly after the treatment course
Week 1-4 (during and after treatment)
What you might notice
- •Improved immune resilience — potentially fewer or shorter duration of common infections
- •Enhanced recovery from illness or physical stress
- •Improved energy levels and reduced fatigue as immune function normalizes
- •Better digestive function from enhanced enzyme activity
What's normal
- •SIRT1 protein levels are significantly elevated (up to 8.2-fold), enhancing DNA repair and stress resistance
- •T-cell maturation (CD4+ and CD8+) is enhanced from thymocyte activation
- •Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are significantly reduced
- •These molecular changes translate into functional immune improvements over weeks
What's next
- →Benefits continue to develop for weeks after the treatment course ends
- →Epigenetic modifications to SIRT1/PARP gene expression persist beyond active treatment
- →Plan the next course in 3-6 months to reinforce and extend benefits
Month 1-6 (inter-course period)
What you might notice
- •Sustained improvements in immune function and overall resilience
- •Ongoing geroprotective benefits from persistent SIRT1 upregulation
- •Reduced frequency and severity of age-related immune dysfunction
- •Benefits may gradually diminish over months, indicating readiness for the next course
What's normal
- •Epigenetic modifications persist beyond the active treatment period
- •Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
- •Each subsequent course reinforces and extends the benefits from previous treatments
- •Long-term clinical follow-up supports sustained benefits with repeated courses
What's next
- →Begin the next Vilon course after 3-6 months
- →Consider combining with complementary bioregulators in rotation
- →Comprehensive anti-aging protocols may use Vilon alongside Epithalon, Cerluten, and others
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Vilon over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging"
Khavinson VK, Linkova NS, Ashapkin VV, 2023
Finding: Vilon peptide (KE) regulates longevity genes by activating SIRT1 and suppressing aging-related PARP1/PARP2, with anti-aging effects mediated through DNA binding.
View Study"The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19"
Linkova N, Khavinson V, Diatlova A, 2023
Finding: Research (2023) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line"
Avolio F, Martinotti S, Khavinson VK, 2022
Finding: Chonluten peptide and other tissue-specific peptides suppress TNF and inflammatory cytokines in immune cells, acting as natural inducers of inflammation tolerance during infections and tissue damage.
View Study"Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells"
Sevostianova NN, Linkova NS, Polyakova VO, 2013
Finding: Research (2013) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway"
Khavinson VKh, Rybakina EG, Malinin VV, 2002
Finding: Research (2002) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
View StudyFrequently Asked Questions